Wilmington Healthcare appoints new Head of Digital
January 26, 2021 |
Wilmington Healthcare, which provides data, insight and intelligence for pharma and medtech companies, has appointed Pfizer’s former UK Digital Marketing Manager, Mikko Figura, as Head of Digital.
In his new role, Mikko will develop and drive the strategy and execution of our clients’ intelligence-led and data-driven omni-channel programmes. These combine multiple channels, including OnMedica – an online community providing bitesize, evidence-based Continuing Professional Development (CPD) and other content for GPs and specialist doctors.
Mikko joins Wilmington Healthcare from the Brain Tumour Charity where, as Head of Digital, he led a team responsible for delivering digital marketing and communications plans across the organisation for income generation and to support service delivery.
Prior to that, he was UK Digital Marketing Manager for Pfizer, where he developed the digital strategy for its UK Rare Diseases Business Unit, which became one of the company’s most successful digital engagement ventures, with initiatives such as patient mobile apps, interactive digital detail aids for sales representatives, and a series of multichannel marketing campaigns.
He also led a team of cross functional stakeholders and external agencies to deliver a consumer-facing multichannel awareness campaign for a rare disease, winning a Pfizer global innovation award in the process.
Mikko has also held roles in digital marketing, customer acquisition, and supporter retention at organisations across a range of industries, including publishing, politics, and B2B service delivery.
Simon Grime, of Wilmington Healthcare, says: “We’re delighted to have Mikko on the team and, having worked in both the pharma and healthcare charity sectors, he brings a really valuable blend of digital marketing experience to his new post.
“He will be a fantastic addition to the company, where he will play a key role in shaping our intelligence-led omni-channel marketing strategy and helping our clients deliver the optimal mix of channels to complement their customer engagement strategies.”
Ends
This content was provided by Wilmington Healthcare
Company Details
Latest Content from Wilmington Healthcare
Considering a portfolio review?
Are you considering a portfolio review for your established pharmaceutical brands? Wondering if you should put some activity behind them? At CHASE our experienced team will ensure you maximise your...
UNDERSTANDING THE ROLE OF PLACE WITHIN THE NEW NHS: FIVE THINGS INDUSTRY NEEDS TO KNOW
Operating a level below system, “place” is an increasingly important unit of NHS organisation, yet it remains an evolving concept that is not always well-understood among industry practitioners. In this...
MISSION CRITICAL: HOW PHARMA CAN HELP THE NHS IMPROVE CARE FOR OLDER PEOPLE
With around two-thirds of all hospital beds occupied by over-65s, the care of older patients has long been recognised as key to the sustainability of the NHS. So how is...
ALL CHANGE FOR SPECIALISED COMMISSIONING: FOUR THINGS INDUSTRY NEEDS TO KNOW ABOUT THE LATEST REFORMS
With a recent NHSEI policy document confirming that a major shake-up of arrangements for Specialised Commissioning is imminent, Oli Hudson, Content Director at Wilmington Healthcare (wilmingtonhealthcare.com), describes the key changes...
HOW DID COVID-19 AFFECT PRESCRIBING BEHAVIOURS? FIVE KEY FINDINGS FROM A NEW STATE OF THE NATION REVIEW
Published earlier this month, Wilmington Healthcare’s new State of the Nation report draws on a raft of data from across primary and secondary care to show what actually happened to...
ALL SYSTEMS GO: UNDERSTANDING WHO’S WHO IN THE NEW NHS LANDSCAPE
With the Health and Care Act safely passed, Oli Hudson introduces six key stakeholders that will loom large in the new landscape.
Spending on anti-depressants soars as the pandemic’s effect on NHS prescribing patterns is revealed
Wilmington Healthcare’s State of the Nation prescribing report shows that spending on sertraline, commonly used to treat depression and anxiety, increased by 305.5% between 2019/20 and 2020/21 while overall spend...
EQUAL FOOTING: HOW PHARMA CAN HELP THE NHS TO ACT ON HEALTH INEQUALITIES
As the NHS puts a renewed focus on reducing health inequalities, Oli Hudson looks at what opportunities this might it bring for Industry and how it can best play its...
UNDERSTANDING THE NEW VALUE PROPOSITION FOR THE NHS
Industry needs a new way of describing its commercial propositions in response to the changing NHS landscape, argues Wilmington Healthcare’s Oli Hudson. This ‘new value proposition’ needs to be reflected...